摘要
目的评价米氮平与舍曲林治疗颅脑外伤后抑郁症的疗效和安全性。方法60例经CCMD-3诊断标准确诊为颅脑外伤后抑郁症的患者,分别接受米氮平或舍曲林治疗,疗程为6 wk,用HAMD和副反应量表(TESS)评估和比较这2种药物治疗颅脑外伤后抑郁症的疗效和安全性。结果经过6 wk的治疗,米氮平组有效率和治愈率分别为86.7%、76.7%,舍曲林组分别为86.7%、80.0%,2组差异无统计学意义(P>0.05)。而2组内HAMD总分治疗前后比较差异有高度统计学意义(P<0.01)。治疗后1 wk末米氮平组的有效率高于舍曲林组,差异有统计学意义(P>0.05)。米氮平组TESS总分为(7.95±2.6)分,舍曲林组为(6.31±2.64)分,P<0.05。结论米氮平和舍曲林对颅脑外伤后抑郁治疗均有效且安全。米氮平起效较快。
AIM To evaluate the therapeutic effect and safety of mirtazapine and sertraline in treatment of depression after craniocerebral trauma. METHODS Sixty depression patients after craniocerebral trauma according to CCMD-3 criteria were enrolled in this study . Thirty patients were given mirtazapine, and another thirty patients were given sertraline for 6 wk. All the patients were evaluated with HAMD and TESS. Antidepressive effect was compared between two drugs. RESULTS At the end of 6 wk of treatment, there were no significant differences between the effective rates and cure rates of mirtazapine group （86.7%, 76.7%） and those of sertraline group （86.7%, 80.0%） （ P 〉 0.05）. The scores of HAMD after 6 wk of treatment were significantly lower than those before treatment both in mirtazapine group and in sertraline group, respectively （P 〈 0.01 ）. The frequencies of somnolence in mirtazapine group were much higher than those in sertraline group , and the frequencies of sleepless of sertraline group were significantly higher than those of mirtazapine group（ P 〈 0.05）. CONCLUSION Mirtazapine and sertraline are safe and effective in the treatment of depression after craniocerebral trauma.
出处
《中国临床药学杂志》
CAS
2007年第4期204-206,共3页
Chinese Journal of Clinical Pharmacy
关键词
颅脑外伤后抑郁
米氮平
舍曲林
depression after craniocerebral trauma
mirtazapine
sertraline
